One To Watch
Personalis
Company Overview
A genomics company whose whole-genome molecular residual disease test, NeXT Personal, has attracted a $1.5 billion acquisition offer from AI-driven precision oncology platform Tempus AI, pending stockholder and regulatory approval. Personalis (Nasdaq: PSNL) built its commercial identity around advanced cancer genomics, serving three distinct customer segments: clinical oncologists ordering MRD surveillance tests, biopharmaceutical companies running oncology trials, and large-scale population sequencing programs. Its "Win-in-MRD" strategy, articulated under current CEO Christopher Hall, is the thesis Tempus is buying into, at a meaningful premium to where the stock spent most of its independent life.
Headquarters and Global Presence
Personalis is headquartered in Menlo Park, California, and operates a CAP-accredited, CLIA-certified laboratory that processes both clinical tests and biopharma research samples. The company has been a sequencing provider to the US Department of Veterans Affairs since 2012, giving it a durable federal presence alongside its commercial oncology business.
Founding and History
Personalis was incorporated in Delaware in February 2011 and priced its initial public offering on June 19, 2019, listing on the Nasdaq Global Select Market under the ticker PSNL at $17.00 per share. On July 20, 2026, Tempus AI announced a definitive merger agreement to acquire Personalis at $16.25 per share, implying an enterprise value of approximately $1.5 billion, with closing expected in late 2026 or early 2027. Personalis continues to trade as an independent company pending the required stockholder vote, HSR antitrust clearance, and other conditions.
Therapy Areas and Focus
Personalis is focused exclusively on oncology, specifically on detecting molecular residual disease, microscopic traces of cancer that persist or return after treatment, and on cancer immunogenomics for biopharma research. The clinical rationale is straightforward: earlier detection of recurrence, particularly in patients with early-stage or low-shedding tumors, gives oncologists a meaningful window to intervene before radiographic relapse. Medicare coverage secured for breast cancer surveillance in late 2025 and for Stage I to III non-small cell lung cancer surveillance in early 2026 validates the clinical and reimbursement case.
Technology Platforms and Modalities
Personalis' core technology differentiator is whole-genome sequencing as the basis for its tumor-informed liquid biopsy, in contrast to the exome or targeted-panel sequencing used by most competing MRD platforms. NeXT Personal constructs a personalized blood-based panel for each patient tracking thousands of tumor variants simultaneously, achieving sensitivity down to one circulating tumor DNA molecule in one million, approximately 10- to 100-fold more sensitive than other available technologies. The ImmunoID NeXT platform serves biopharma customers differently: it consolidates multiple biomarker assays into a single tissue sample readout across approximately 20,000 human genes plus immune system profiling, useful for immunotherapy development programs.
Key Pipeline and Programs
NeXT Personal Dx is the company's flagship laboratory developed test, a tumor-informed, whole genome-based liquid biopsy run at its CLIA-certified laboratory, designed for clinical detection of MRD and cancer recurrence. It has secured Medicare coverage for breast cancer surveillance and Stage I to III NSCLC surveillance, its two largest near-term commercial opportunities, within a six-month span in late 2025 and early 2026. Clinical volume reached more than 7,800 tests in Q1 2026, up 258% year over year, with more than 1,000 ordering physicians, the clearest signal yet that reimbursement is translating into actual uptake. NeXT Dx is the company's comprehensive genomic cancer profiling test, while ImmunoID NeXT serves as the biopharma-facing cancer immunogenomics platform, profiling approximately 20,000 human genes alongside immune system data from a single tissue sample to support trial biomarker strategies and immunotherapy response prediction. Clinical evidence for NeXT Personal has been generated through the TRACERx lung cancer study, and research collaborations with BC Cancer cover colorectal and pancreatic ctDNA testing.
Recent Developments
The defining event of 2026 is the July 20 announcement of Tempus AI's agreement to acquire Personalis at $16.25 per share, implying a roughly $1.5 billion enterprise value, and a deal that formalizes what had been a commercial co-promotion partnership since November 2023. In Q1 2026, Personalis received Medicare coverage for NSCLC recurrence surveillance and reported clinical volume up 258% year over year, reinforcing the commercial momentum underpinning the deal's rationale. Full year 2025 revenue of approximately $69 million to $70 million came with nearly 400% clinical volume growth and a year-end cash balance of approximately $240 million; 2026 guidance is $78 million to $80 million. The Tempus transaction remains pending, with an outside date of April 20, 2027.
Key Personnel
Christopher Hall serves as Chief Executive Officer and President, having joined Personalis in October 2022 and assumed the CEO role formally in March 2023. Aaron Tachibana, who joined in 2019 and led the company through its IPO as CFO, now holds a dual role as Chief Financial Officer and Chief Operating Officer. Dr. Richard Chen, a Personalis veteran since 2011, serves as Executive Vice President, R&D and Chief Medical Officer, bridging the scientific and clinical functions.
Strategic Partnerships
Tempus AI has been Personalis' exclusive commercial diagnostic partner for NeXT Personal Dx since the November 2023 strategic collaboration, an arrangement that also saw Tempus take an equity stake in the company, and that now forms the direct foundation for the pending $1.5 billion acquisition. US drugmaker Merck & Co made an approximately $50 million private placement investment in Personalis at $3.56 per share in December 2024 and, holding approximately 13% of voting power, has signed a voting agreement committing to support the Tempus merger. Moderna has worked with Personalis on cancer testing services supporting immunotherapy development. The US Department of Veterans Affairs has engaged Personalis as a sequencing provider for its Million Veteran Program since 2012, with cumulative task orders reaching approximately $175 million.
FAQ Section
Tempus and Personalis jointly describe MRD monitoring as an approximately $20 billion addressable market, and Tempus is buying the whole-genome sensitivity advantage that NeXT Personal Dx brings, a capability its existing AI-driven precision oncology platform lacks. The deal formalizes a commercial partnership established in 2023 under which Tempus was already the exclusive distribution partner for NeXT Personal Dx, meaning Tempus has direct visibility into the test's clinical traction. With clinical volumes up nearly 400% in 2025 and Medicare coverage now in place for two major tumor types, Tempus is acquiring demonstrated momentum rather than a speculative asset.
Most competing MRD platforms rely on targeted panels or exome sequencing, which limits both the number of variants tracked and sensitivity in low-shedding or low-mutational-burden tumors. Personalis' whole-genome approach allows NeXT Personal to simultaneously track thousands of tumor variants in a single personalized panel, achieving sensitivity to one ctDNA molecule per million, roughly 10- to 100-fold better than alternative technologies. That sensitivity gap matters most for early-stage cancers, where ctDNA shedding is minimal and where earlier detection has the greatest potential clinical impact.
The primary differentiator is the combination of whole-genome sequencing with a fully personalized panel architecture, since each test is built around each individual patient's tumor mutation profile, rather than a fixed set of cancer-associated targets. This design allows NeXT Personal Dx to function across a broader range of cancer types and stages than panel-based competitors. The CAP/CLIA-certified laboratory infrastructure and the existing Medicare coverage for breast and NSCLC surveillance also represent meaningful commercial moats that take years to build.
NeXT Personal Dx secured Medicare coverage for breast cancer recurrence surveillance in Q4 2025 and for Stage I to III non-small cell lung cancer recurrence surveillance in Q1 2026, two of the highest-volume post-treatment surveillance populations in oncology. Clinical test volume in Q1 2026 exceeded 7,800 tests, up 26% sequentially and 258% year over year, with more than 1,000 physicians ordering the test.
Beyond clinical MRD surveillance, Personalis serves the biopharma sector through ImmunoID NeXT, a cancer immunogenomics platform that profiles approximately 20,000 human genes alongside immune system data from a single tissue sample, useful for trial biomarker strategy and immunotherapy response prediction. Research collaborations in colorectal, pancreatic, gastroesophageal, and lung cancers (including TRACERx) expand the evidence base. Population genomics for the VA's Million Veteran Program, with cumulative task orders of approximately $175 million, constitutes a third, distinctly durable revenue line.
Personalis is a commercially launched, revenue-generating company reporting approximately $69 million to $70 million in 2025 revenue and guiding to $78 million to $80 million in 2026, with approximately $240 million in cash at year-end 2025. As an independent entity it was executing well, with clinical volume growth of nearly 400% in 2025 materially exceeding its own guidance. Under Tempus, NeXT Personal Dx would be integrated into an AI-enabled precision oncology platform with broader commercial reach, though until the merger closes Personalis continues to operate and report independently.
The principal watchpoints for Personalis through the anticipated closing period are:
- Personalis stockholder vote approving the merger, expected before the April 20, 2027 outside date
- HSR antitrust clearance, standard for a deal of this size in the diagnostics-genomics space
- Tempus stock price relative to the $46.00 floor: if Tempus shares fall below this level, Personalis has a termination right, reintroducing standalone-trajectory risk
- Continued clinical volume growth and any additional Medicare or payer coverage decisions for further tumor types, which would affect standalone valuation if the deal does not close
- Merck's approximately 13% voting block has already committed to vote in favor, reducing approval risk on that front
Today's issue
| Headless Content Management with Blaze